NTLA · Intellia Therapeutics, Inc.

Intellia Therapeutics executed a follow-on public offering under its effective S-3 shelf registration, entering into an underwriting agreement on April 28, 2026, with lead underwriters Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. The firm commitment covered 16,744,187 shares of common stock priced at $10.75 per share to the public, with the underwriters fully exercising their 30-day over-allotment option for an additional 2,511,628 shares on April 29, 2026. The transaction closed on April 30, 2026, generating approximately $194.6 million in net proceeds after underwriting discounts, commissions, and estimated offering expenses. This capital infusion significantly bolsters the company's liquidity position, which stood at $517.2 million in preliminary unaudited cash, cash equivalents, and marketable securities as of March 31, 2026, further supported by $33.6 million raised via an at-the-market program during the same quarter. Management intends to deploy the proceeds toward advancing clinical development of lead programs, including preparations for the anticipated commercial launch of lonvoguran ziclumeran for hereditary angioedema in the first half of 2027, alongside R&D for other pipeline candidates, potential acquisitions, working capital, and general corporate needs. Critically, this funding, combined with existing resources and collaboration reimbursements, extends the cash runway at least into 2028, excluding potential milestone payments, extension fees, or product revenues post-approval. The offering includes standard representations, warranties, covenants, and indemnification provisions under the Securities Act, with legal opinions from Goodwin Procter LLP confirming the shares' validity. Item 2.02 provides preliminary balance sheet context but no audited income statement results, emphasizing the financing's role in sustaining operations through key milestones.